Business Wire

GA-INVERIS-TRAINING-SOLU

29.11.2021 20:02:11 CET | Business Wire | Press release

Share
InVeris Training Solutions Unveils SRCE™ – a Revolutionary, Augmented Reality Training System

InVeris Training Solutions, the leading provider of integrated live-fire and virtual weapons training systems for military, law enforcement agencies and commercial shooting ranges, today unveils SRCE™ (See, Rehearse, Collectively Experience or "Source"), a groundbreaking, augmented reality-based, untethered weapons training simulator. InVeris Training Solutions provides the most advanced augmented reality technology available in a military and law enforcement training simulator, a feat previously thought to be years away by many in the industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005628/en/

"Augmented reality delivers the best of the virtual and real worlds in a way that's fully lifelike, seamless, customizable and economical," said InVeris CEO Al Weggeman. "Physical training facilities can be scanned and augmented to become instant shoot houses by integrating outside content in just minutes. More importantly, we can compare and measure individual and team performance with high precision real-time location tracking of every participant, weapon and even ammunition round."

Critical, use-of-force training can now occur at the point of need or anywhere in the world. This never-experienced complete immersive technology delivers a way to see, rehearse and collectively experience techniques, tactics and procedures with real-time location, movement, orientation and biometric sensing for training and operations. SRCE's proprietary scanning technology allows an instructor to capture the space intended for use as a shoot house using a tablet or other device with a high-resolution camera. Hostile forces, suspects, decoys, hostages, and other parties are all delivered digitally, eliminating the need for opposition role players. SRCE's ability to create a virtual shoot house on the fly lends to active shooter and mission rehearsal training. Wearable, untethered technology, including an AR head-mounted display, provides realistic immersion without compromising freedom of movement and is fully compatible with InVeris' highly accurate BlueFire® simulated weapons.

The unparalleled interactive after-action review (AAR) collects performance data for statistical analysis of never-before-available parameters, including muzzle direction, weapon discharge, missed rounds, eye tracking and head placement. Body sensors monitor a trainee's heart rate, breathing, gaze and other biological signs in real-time. Trainees can even walk through their previous session, seeing every element played back around them as a visualization to review operational performance. This highly immersive AAR creates the optimal opportunity for instructors to increase training fidelity and retention.

For more information on SRCE, visit https://www.inveristraining.com/srce .

About InVeris Training Solutions

InVeris Training Solutions provides cutting-edge training solutions for militaries, law enforcement agencies and commercial range owners around the world. With its legacy companies, FATS® and Caswell, InVeris Training Solutions has fielded over 15,500 live-fire ranges and 7,500 virtual systems globally during its 95-year history. The company is headquartered in Suwanee, Georgia and partners with clients in the U.S. and around the world from facilities on five continents.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 14:00:00 CEST | Press release

Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye